PDZK1‐ULK1 Axis Triggers Lipophagy to Inhibit Tumor Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
Advanced Science · 2026
DOI: 10.1002/advs.202511606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xuan Qi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology Beijing Key Laboratory for Tumor Invasion and Metastasis, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Autophagy-Related Protein-1 Homolog, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of the People's Republic of China, Beijing Municipal Natural Science Foundation, Natural Science Foundation of Shanxi Province.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is characterized by aberrant lipid droplet (LD) accumulation, which promotes tumor progression and sunitinib resistance. However, the underlying molecular mechanisms remain incompletely understood. This study shows that reduced PDZK1 expression correlates with LD accumulation and poor prognosis in ccRCC patients. Single‐cell RNA sequencing indicates that downregulated PDZK1 expression associates with impaired LD degradation in ccRCC cells. Functional studies demonstrate that PDZK1 inhibits LD accumulation by upregulating ULK1 expression and activating lipophagy, indicating the PDZK1‐ULK1 axis as a therapeutic target to enhance sunitinib efficacy. Mechanistically, CUT&Tag analysis reveals that LEF1 directly binds to the ULK1 promoter. PDZK1 interacts with LEF1 via its C‐terminus, sequestering LEF1 in the cytoplasm, thereby enhancing ULK1 transcription and autophagy activity. Pharmacological ULK1 activation with LYN‐1604 restores sunitinib sensitivity in PDZK1‐knockdown cells and synergizes with sunitinib in xenograft models, reducing tumor growth and LD accumulation. Clinical data demonstrate a strong correlation between ULK1 expression levels in tumor tissues and sunitinib response (AUC = 0.9063), suggesting its potential as a predictive biomarker. Collectively, the PDZK1‐ULK1 axis regulates LD homeostasis in ccRCC. Targeting this axis via ULK1 activation represents a novel strategy to overcome sunitinib resistance, with ULK1 as a potential biomarker for sunitinib efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology Beijing Key Laboratory for Tumor Invasion and Metastasis, Capital Medical University, Beijing, China.
- Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
- Department of Interventional Radiology, First Hospital of Shanxi Medical University, Taiyuan, China.
Förderung
- National Natural Science Foundation of the People's Republic of China
- Beijing Municipal Natural Science Foundation
- Natural Science Foundation of Shanxi Province
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Qi, X., Guo, Y., Yang, Y., Wang, H., Yang, X., Song, R., Qin, Q., Zhang, Y., Hu, M., Zhou, H., Feng, D., & He, J. (2026). PDZK1‐ULK1 Axis Triggers Lipophagy to Inhibit Tumor Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202511606
Vancouver
Qi X, Guo Y, Yang Y, Wang H, Yang X, Song R, et al. PDZK1‐ULK1 Axis Triggers Lipophagy to Inhibit Tumor Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Advanced Science. 2026. doi:10.1002/advs.202511606
BibTeX
@article{Qi2026,
author = {Qi, Xuan and Guo, Yu and Yang, Yumeng and Wang, Haibo and Yang, Xiaomei and Song, Ran and Qin, Qiong and Zhang, Yan and Hu, Meihan and Zhou, Haixing and Feng, Duiping and He, Junqi},
title = {PDZK1‐ULK1 Axis Triggers Lipophagy to Inhibit Tumor Progression and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202511606}
}
EUVIMED